Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension

Cardiovascular Research

Volumn 28, Issue 11, 1994, Pages 1720-1725

  Calver, Alison ^a   Collier, Joe ^a   Vallance, Patrick ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antihypertensive therapy; Blood pressure; Forearm blood flow; L NMMA; Nitric oxide

Indexed keywords

AMLODIPINE; ENALAPRIL; LISINOPRIL; N(G) METHYLARGININE; NITRIC OXIDE; NORADRENALIN;

ADULT; ARM BLOOD FLOW; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; VASODILATATION;

ADULT; AGED; AMINO ACID OXIDOREDUCTASES; ARGININE; FEMALE; FOREARM; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NOREPINEPHRINE; OMEGA-N-METHYLARGININE; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; VASODILATION;

EID: 85047678216     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1093/cvr/28.11.1720     Document Type: Article

References (35)

1. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524–6.
2. G-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989;160:881–6.
3. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375–8.
4. Vallance P, Collier J, Moneada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;ii:997–1000.
5. Palmer RMJ, Ashton DS, Moneada S. Vascular endothelial cells synthesise nitric oxide from L-arainine. Nature 1988;333:664–6.
6. Palmer RMJ, Moneada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989;158:348–52.
7. Moneada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109–42.
8. Rees DD, Palmer RMJ, Hodson HF, Moneada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989;96:418–24.
9. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears impaired. J Hypertens 1992;10:1025–31.
10. Dohi Y, Thiel MA, Bühler FR, Lüscher TF. Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension 1990;15:170–9.
11. Winquist RJ, Bunting PB, Baskin EP, Wallace AA. Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive rats. J Hypertens 1984;2:541–5.
12. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990;81:1762–7.
13. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22–7.
14. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468–74.
15. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 1990;16:532–40.
16. Dohi Y, Criscione L, Pfeiffer K, Lüscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. J Vasc Res 1992;29:105.
17. Whitney RJ. The measurement of volume changes in human limbs. J Physiol (Lond) 1953;121:1–27.
18. Greenfield ADM, Patterson GC. Reactions of the blood vessels of the human forearm to increases in transmural pressure. J Physiol (Lond) 1954;125:508–24.
19. Calver AL, Collier JG, Vallance PJT. Inhibition and stimulation of nitric oxide synthesis in the forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548–54.
20. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230–5.
21. G-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994;12:1047–52.
22. Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilatation in hypertensive patients. Hypertension 1992;20:175–80.
23. Creager MA, Roddy M-A, Coleman SM, Dzau VJ. The effect of ACE inhibition on endothelium-dependent vasodilatation in hypertension. J Vase Res 1992;29:97.
24. Miller VM. Does antihypertensive therapy improve the function of the vascular endothelium? Hypertension 1990;16:541–3.
25. Hamilton M, Thompson EN, Wisniewski TKM. The role of blood pressure control in preventing complications of hypertension. Lancet 1964;i:235–8.
26. Veterans Administration Co-operative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 1967;202:1028–34.
27. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97–104.
28. Motz W, Strauer BE. Regression of structural cardiovascular changes by antihypertensive therapy. Hypertension 1984;6 (suppl III):III–133–9.
29. Heagerty AM, Bund SJ, Aalkjaer C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. Lancet 1988;ii:1209–12.
30. Anderson PG, Bishop SP, Digerness SB. Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res 1989;64:1127–36.
31. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens 1989;7:83–90.
32. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774–7.
33. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;147:1482–9.
34. Radomski MW, Palmer RMJ, Moneada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057–8.
35. Radomski MW, Palmer RMJ, Moneada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639–46.